A Universal protein tag for delivery of SiRNA-Aptamer Chimeras

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Liu, Hong Yan ^a   Gao, Xiaohu ^a  

^a University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CARRIER PROTEIN; HYBRID PROTEIN; SMALL INTERFERING RNA;

CELL LINE; CHEMISTRY; GENE EXPRESSION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PROTEIN DOMAIN; REPORTER GENE; SYNTHESIS;

APTAMERS, NUCLEOTIDE; CARRIER PROTEINS; CELL LINE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENES, REPORTER; HUMANS; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING;

EID: 84889581080     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03129     Document Type: Article

References (50)

1. Dykxhoorn, D. M., Novina, C. D. & Sharp, P. A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4, 457-467 (2003) (Pubitemid 36648591)
2. Hannon, G. J. RNA interference. Nature 418, 244-251 (2002) (Pubitemid 34773784)
3. Scherer, L. J. & Rossi, J. J. Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol. 21, 1457-1465 (2003) (Pubitemid 37522705)
4. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138 (2009)
5. Chiu, Y. L., Ali, A., Chu, C. Y., Cao, H. & Rana, T. M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 11, 1165-1175 (2004) (Pubitemid 39138769)
6. Jeong, J. H., Mok, H., Oh, Y. K. & Park, T. G. siRNA conjugate delivery systems. Bioconjug. Chem. 20, 5-14 (2009)
7. Moschos, S. A. et al. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem. 18, 1450-1459 (2007) (Pubitemid 47464052)
8. Nishina, K. et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 16, 734-740 (2008) (Pubitemid 351426175)
9. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004) (Pubitemid 39545841)
10. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149-1157 (2007) (Pubitemid 47538115)
11. Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H. & Toole, J. J. Selection of single-stranded-DNA molecules that bind and inhibit human thrombin. Nature 355, 564-566 (1992)
12. Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822 (1990)
13. Hermann, T. & Patel, D. J. Biochemistry-Adaptive recognition by nucleic acid aptamers. Science 287, 820-825 (2000) (Pubitemid 30084318)
14. Nimjee, S. M., Rusconi, C. P. & Sullenger, B. A. in Annual Rev. Med. 56, 555-583 (2005)
15. Dassie, J. P. et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol 27, 839-849 (2009)
16. McNamara, J. O. 2nd et al. Cell type-specific delivery of siRNAs with aptamersiRNA chimeras. Nat. Biotechnol. 24, 1005-1015 (2006) (Pubitemid 44215395)
17. Levy-Nissenbaum, E., Radovic-Moreno, A. F., Wang, A. Z., Langer, R. & Farokhzad, O. C. Nanotechnology and aptamers: Applications in drug delivery. Trends Biotechnol. 26, 442-449 (2008)
18. Derfus, A. M., Chen, A. A., Min, D. H., Ruoslahti, E. & Bhatia, S. N. Targeted quantum dot conjugates for siRNA delivery. Bioconjug. Chem. 18, 1391-1396 (2007) (Pubitemid 47464045)
19. Elbakry, A. et al. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett. 9, 2059-2064 (2009)
20. Medarova, Z., Pham, W., Farrar, C., Petkova, V. & Moore, A. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 13, 372-377 (2007) (Pubitemid 46376679)
21. Meng, H. et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4, 4539-4550
22. Xia, T. et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3, 3273-3286 (2009)
23. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515 (2008)
24. Bagalkot, V. & Gao, X. siRNA-aptamer chimeras on nanoparticles: Preserving targeting functionality for effective gene silencing. ACS Nano 5, 8131-8139 (2011)
25. Walter, J.-G., KoÌkpinar, O. Z., Friehs, K., Stahl, F. & Scheper, T. Systematic Investigation of Optimal Aptamer Immobilization for Proteinâ'Microarray Applications. Anal. Chem. 80, 7372-7378 (2008)
26. Bevilacqua, P. C. & Cech, T. R. Minor-groove recognition of double-stranded RNA by the double-stranded RNA-binding domain from the RNA-activated protein kinase PKR. Biochemistry 35, 9983-9994 (1996) (Pubitemid 26269913)
27. Eguchi, A. et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol. 27, 567-U110 (2009)
28. Pichon, C., Goncalves, C. & Midoux, P. Histidine-rich peptides and polymers for nucleic acids delivery. Adv. Drug Del. Rev. 53, 75-94 (2001) (Pubitemid 33152834)
29. Midoux, P., Pichon, C., Yaouanc, J. J. & Jaffres, P. A. Chemical vectors for gene delivery: A current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol. 157, 166-178 (2009)
30. Behr, J. P. The proton sponge: A trick to enter cells the viruses did not exploit. Chimia 51, 34-36 (1997)
31. Nanduri, S., Carpick, B. W., Yang, Y. W.,Williams, B. R. G. & Qin, J. Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. Embo J. 17, 5458-5465 (1998) (Pubitemid 28427059)
32. Green, S. R. &Mathews, M. B. 2 Rna-BindingMotifs in theDouble-Stranded Rna-Activated Protein-Kinase, Dai. Genes Dev. 6, 2478-2490 (1992) (Pubitemid 23052877)
33. Kim, I., Liu, C. W. & Puglisi, J. D. Specific recognition of HIV TAR RNA by the dsRNA binding domains (dsRBD1-dsRBD2) of PKR. J. Mol. Biol. 358, 430-442 (2006)
34. Kim, J., Lee, S. H., Choe, J. & Park, T. G. Intracellular small interfering RNA delivery using genetically engineered double-stranded RNA binding protein domain. J. Gene Med. 11, 804-812 (2009)
35. Ko, Y. T., Kale, A., Hartner, W. C., Papahadjopoulos-Sternberg, B. & Torchilin, V. P. Self-assembling micelle-like nanoparticles based on phospholipidpolyethyleneimine conjugates for systemic gene delivery. J. Controlled Release 133, 132-138 (2009)
36. Chang, S. S., Reuter, V. E., Heston, W. D. W. & Gaudin, P. B. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 57, 801-805 (2001)
37. Nallagatla, S. R. & Bevilacqua, P. C. Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA 14, 1201-1213 (2008) (Pubitemid 351717499)
38. Davis, M. E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharm. 6, 659-668 (2009)
39. Green, J. J. et al. Electrostatic Ligand Coatings of Nanoparticles Enable Ligand-Specific Gene Delivery to Human Primary Cells. Nano Lett. 7, 874-879 (2007) (Pubitemid 46717725)
40. Howard, K. A. et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476-484 (2006) (Pubitemid 44296092)
41. Liu, X. et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28, 1280-1288 (2007) (Pubitemid 44816373)
42. Qi, L. & Gao, X. Quantum dot-amphipol nanocomplex for intracellular delivery and real-time imaging of siRNA. ACS Nano 2, 1403-1410 (2008)
43. Qi, L. & Gao, X. Emerging application of quantum dots for drug delivery and therapy. Exp. Opin. Drug Del. 5, 263-267 (2008) (Pubitemid 351454377)
44. Probst, C. E., Zrazhevskiy, P., Bagalkot, V. & Gao, X. H. Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv. Drug Del. Rev. 65, 703-718 (2013)
45. Bitko, V., Musiyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11, 50-55 (2005) (Pubitemid 40215837)
46. DeVincenzo, J. et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 77, 225-231 (2008)
47. Li, B. J. et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. Nat. Med. 11, 944-951 (2005)
48. Reich, S. et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vision 9, 210-216 (2003) (Pubitemid 38097589)
49. Longmire, M., Choyke, P. L. & Kobayashi, H. Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats. Nanomedicine 3, 703-717 (2008)
50. Cabral, H. et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6, 815-823 (2011)